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The Relationship between Plasma Homocysteine and
Early Coronary Collateral Vessel Development after
Acute Myocardial Infarction
Aim: Homocysteine is known to inhibit endothelial cell proliferation, which is a key event in angiogenesis.
Factors responsible for the presence or absence of coronary collateral circulation are poorly understood.
Therefore, in this study we investigated the effect of plasma homocysteine level on the early formation of
angiographically visible collaterals after acute myocardial infarction.
Materials and Methods: The study included 60 patients that had ST-segment elevation myocardial infarction
(STEMI). All the patients underwent coronary angiography 1-4 days after admission (mean: 2.3 ± 1.2 days).
Patients were graded according to Rentrop classification. Patients with grade 0 or 1 collateral vessels were
classified as poor collaterals; patients with grade 2 or 3 collateral vessels were classified as good collaterals.
Results: In all, 35 (58.3%) patients had poor collateral vessel filling and the remaining 25 (41.7%) patients
had good collateral filling. Plasma homocysteine concentration in patients with poor and good collateral
formation was 18.2 ± 8.6 μmol/l and 12.7 ± 2.4 μmol/l, respectively (P = 0.008). There was a negative linear
correlation between Rentrop subclasses and plasma homocysteine concentration (r = –0.391, P = 0.002). We
assessed the effect of demographic variables, such as age, gender, hypertension, diabetes mellitus, smoking,
lipid parameters, and plasma homocysteine concentration, on the development of collaterals. The only
independent variable that affected the development of collaterals was homocysteine level (OR: 0.71; 95% CI
= 0.57-0.89, P = 0.003).
Conclusions: This study demonstrates for the first time that there is an inverse relationship between the early
development of collateral circulation after acute myocardial infarction and plasma homocysteine concentration.
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Homosistein ve Akut Miyokard İnfarktüsü Sonrası Erken Dönemde Koroner
Kollateral Gelişimi
Amaç: Homosisteinin endotelyal hücre proliferasyonunu inhibe ettiği bilinmektedir. Koroner kollateral
dolaşımın gelişimini etkileyen faktörler iyi bilinmemektedir. Bu çalışmada plazma homosistein düzeylerinin
akut miyokard infarktüsü sonrası anjiyografik olarak saptanabilen kollaterallerin gelişimi üzerine tekisi
araştırılmıştır.
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Yöntem ve Gereç: Çalışmaya akut ST yükselmeli miyokard infarktüsü geçiren 60 hasta alınmıştır. Tüm
hastalara hastaneye yatırıldıktan sonraki 1-4. günler arasında koroner anjiyografi yapılmıştır (ortalama 2,3 ±
1,2 gün). Kollateral damar gelişimi rentrop sınıflamasına göre derecelendirilmiş, 0 ve 1 kötü kollateral
gelişimi, 2 ve 3 ise iyi kollateral gelişimi olarak gruplandırılmıştır.
Bulgular: 35 hastada (% 58,3) kötü kollateral gelişimi saptanmıştır. Geri kalan 25 hastada ise (% 41,7)
kollateral gelişimin iyi olduğu görülmüştür. Ortalama plasma homosistein konsantrasyonu kötü ve iyi kollateral
grublarında sırasıyla 18,2 ± 8,6 μmol/l ve 12,7 ± 2,4 μmol/l bulunmuştur (P = 0,008). Rentrop sınıfı ile
homosistein düzeyi arasında anlamlı negatif korelasyon olduğu görülmüştür (r = –0,391, P = 0,002). Yaş,
cinsiyet, hipertansiyon, diyabet varlığı, sigara alışkanlığı, plazma lipid parametreleri ve homosistein
konsantrasyonlarının kollateral gelişimi üzerine etkisine bakıldığında, kollateral gelişini etkileyen tek bağımsız
değişkenin homosistein olduğu görülmüştür (OR: 0,71; % 95 güven aralığı 0,57-0,89, P = 0,003).
Sonuç: Bu çalışma ile plazma homosistein konsantrasyonları ile akut miyokard infarktüsü sonrası erken
dönemdeki kollateral gelişimi arasındaki negatif ilişkinin varlığı ilk kez gösterilmiştir.

drtelatkeles@yahoo.com
Anahtar Sözcükler: Kollateral dolaşım, homosistein, akut miyokard infarktüsü
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Introduction
Homocysteine is a sulfur-containing amino acid
derived from the demethylation of methionine. The
atherosclerotic role of hyperhomocysteinemia was first
established in 1969 by McCully, who reported premature
extensive atherosclerosis in autopsied children that died
due to homocysteinuria (1). It is now well known that
high-level plasma homocysteine is an independent risk
factor for peripheral vascular, cerebrovascular, and
coronary artery disease (2-5). Hyperhomocysteinemia
may exert multiple adverse effects on the cells of vascular
walls. In several in vitro studies the addition of
homocysteine to culture medium caused endothelial cell
damage in a dose-dependent manner (6,7).
Homocysteine is known to inhibit endothelial cell
proliferation, which is a key event in angiogenesis (8). In
the human heart mixed arteriogenic/angiogenic-type
adaptation is an essential step in the development of
collaterals (9).
The formation of coronary collaterals is an adaptive
response of the coronary vascular system to arterial
occlusion. This process is involved in restoring coronary
blood flow and salvaging the myocardium in ischemic
regions. Previous studies have shown that in cases of
acute myocardial infarction, the presence of collaterals
may limit the size of the infarct, preserve viability, and
prevent ventricular aneurysm formation during an
episode of acute coronary occlusion (10-13). Factors
responsible for the presence or absence of collateral
circulation are poorly understood. Therefore, in the
present study we investigated the effects of plasma
homocysteine level on the early formation of
angiographically visible collaterals after acute myocardial
infarction.
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contiguous precordial leads. STEMI was later confirmed
by serum creatine kinase-MB fractions that increased to
more than twice the upper limit of normal and serum
troponin I levels above the upper limit of normal,
according to the local quantitative or qualitative assays.
Oxygen, aspirin, glyceryl trinitrate, morphine, and betablocker were administered to the patients. In addition,
other appropriate pharmacologic agents were given to all
the patients after thrombolytic therapy, which included
heparin, clopidogrel, statin, and angiotensin enzyme
inhibitor.
Exclusionary criteria were as follows: 1) Patients
with a previous MI; 2) Patients with collateral formation
due to a non-culprit lesion, as seen with coronary
angiography; 3) Patients that previously underwent
CABG or PCI; 4) Patients using folic acid or vitamin B
complex supplements; 5) Patients with a history of folic
acid or vitamin B complex deficiency; 6) Patients with
cancer or renal insufficiency (creatinine ≥ 1.5 mg/dl).
Blood Sampling and Measurement of Plasma
Homocysteine Level
Blood samples were collected from the antecubital
vein at admission. Following coagulation for 1 h at room
temperature, the samples were centrifuged for 10 min at
3000 rpm. The plasma was collected and kept at –70 °C
until further analysis. Total plasma homocysteine level
was determined using high-performance liquid
chromatography
with
fluorescence
detection
(Chromsystems 45000 reagent kit; Agilent 1200,
Germany). Hyperhomocysteinemia was defined as a
plasma homocysteine concentration > 15 μmol/l. Lipid
profiles, glucose, and creatinine concentrations were
determined using routine laboratory methods.
Coronary Angiography and Grading of Coronary
Collateral Filling

Materials and Methods
Patient Selection
The study included 60 patients that had ST-segment
elevation myocardial infarction (STEMI). All the patients
underwent coronary angiography 1-4 days after
admission (mean: 2.3 ± 1.2 days). STEMI was diagnosed
based on chest pain that persisted for more than 20 min
and ST-segment elevation more than 1 mm in at least 2
standard limb leads or more than 2 mm in at least 2
168

Standard angiography with at least 4 views of the left
coronary system and 2 views of the right coronary artery
was used for interpretation. Collateral vessels were
graded according to Rentrop classification: 0, no filling of
any collateral vessel; 1, filling of side branches of the
artery to be perfused by collateral vessels, without
visualization of the epicardial segment; 2, partial filling of
the epicardial artery by collateral vessels; 3, complete
filling of the epicardial artery by collateral vessels (14). All
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angiographies were evaluated independently by 2
cardiologists blinded to the patients’ identities and clinical
data. When there was disagreement, a third cardiologist
blinded to the initial 2 readings served as an arbitrator.
The patients were classified into 2 groups according to
collateral vessel grade. Patients with grade 0 or 1
collateral vessels were classified as poor collaterals;
patients with grade 2 or 3 collateral vessels were
classified as good collaterals.
Statistical Analysis
All statistical analyses were performed with SPSS
v.13.0 (SPSS Inc., Chicago, IL, USA). Continuous
variables were expressed as mean ± SD, and categorical
variables were expressed as percentages. The
Kolmogorov-Smirnov test was used to compare empirical
distribution of continuous variables. Comparison of
continuous variables between groups was performed
using Student’s t-test and one way analysis of variance,
with Bonferroni posteriori comparisons as appropriate.
The chi-square test was used for the analysis of
categorical variables. The relationship between Rentrop
subclasses and plasma homocysteine levels was tested by
Spearman’s correlation. Multivariate logistic regression
analysis was used to determine the independent variables
that affected the development of collaterals. P values less
than 0.05 were considered statistically significant.
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Results
The study population consisted of 60 patients aged
32-77 years (47 males, 13 females). In all, 35 (58.3%)
patients had poor collateral vessel filling and 25 (41.7%)
had good collateral filling. The demographic
characteristics of the study population are shown in the
Table. There were no statistically significant differences
between the groups in terms of gender, age, and lipid
profile, or prevalence of hypertension, diabetes mellitus,
and smoking. Plasma homocysteine concentration in
patients with poor and good collateral formation was
18.2 ± 8.6 μmol/l and 12.7 ± 2.4 μmol/l, respectively (P
= 0.008) (Figure 1). Among the entire study population
there were 18 (30%) patients with grade 0 angiographic
collaterals, 17 (28.3%) patients with grade 1, 17
(28.3%) patients with grade 2, and 8 (13.4%) patients
with grade 3 angiographic collaterals. Mean plasma
homocysteine concentration in individual Rentrop
subclasses 0, 1, 2, and 3 were, respectively, 21 ± 10
μmol/l, 14.8 ± 5.1 μmol/l, 13.1 ± 2.1 μmol/l, and 11.5
± 3.1 μmol/l, (P = 0.001, by ANOVA). There was a
negative linear correlation between Rentrop subclasses
and plasma homocysteine concentrations (r = –0.391,
P = 0.002) (Figure 2).
Among the study population, 24 (40%) patients had
a plasma homocysteine concentration > 15 μmol/l (upper
limit of normal). Of these patients, 20 (83.3%) had poor
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Figure 1. Plasma homocysteine concentration in the poor and good
collateral groups.







Figure 2. Relationship between plasma homocysteine concentration
and Rentrop collateral classification (r = –0.391, P = 0.002).
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Table. Characteristics of the study population.

Age (years)

Poor collateral
n = 35

Good collateral
n = 25

P value

0.207

55 ± 10

58 ± 9

Gender (M/F)

5/30

8/17

0.122

Hypertension

14 (40%)

11 (44%)

0.795

Diabetes Mellitus
Smoking
Family history of CAD

7 (20%)

6 (24%)

0.758

25 (71.4%)

14 (56%)

0.276

8 (22.9%)

8 (32%)

0.384

Total cholesterol (mg/dl)

198.3 ± 43.6

187.1 ± 38.1

0.286

Triglycerides (mg/dl)

165.8 ± 113.4

182.7 ± 108.1

0.564

LDL (mg/dl)

125.5 ± 39

111 ± 29.6

0.124

HDL (mg/dl)

38.4 ± 6.4

37.2 ± 7.6

0.494

LVEF (%)

39.3 ± 9.1

41.3 ± 9.2

0.145

CAD: Coronary artery disease; F: female; HDL: high density lipoprotein, LDL: low-density
lipoprotein; LVEF: left ventricular ejection fraction; M: male.

coronary collaterals, but in patients with a plasma
homocysteine concentration < 15 μmol/l, this rate was
only 41.7% (P = 0.002). Of patients in the good
collaterals group, 84% had a plasma homocysteine
concentration < 15 μmol/l. In the poor collaterals group
42.9% of the patients had a plasma homocysteine
concentration < 15 μmol/l (P = 0.002).
We assessed the effect of demographic variables, such
as age, gender, hypertension, diabetes mellitus, smoking,
lipid
parameters,
and
plasma
homocysteine
concentration, on the development of collaterals. The
only independent variable that affected the development
of collaterals was homocysteine level (OR: 0.71; 95%
CI = 0.57-0.89, P = 0.003).

Discussion
In the present study increased plasma homocysteine
concentration was an independent predictor of poor early
collateral development after acute myocardial infarction.
This is the first study to document that patients with poor
early collateral formation after acute myocardial
infarction had higher levels of plasma homocysteine than
those with good collateral formation.
Coronary collateral circulation is an alternative source
of blood supply to a myocardial area jeopardized by
ischemia. Coronary collateral development has a potential
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protective role due to its association with smaller infarcts,
less ventricular aneurysm formation, improved
ventricular function, fewer future cardiovascular events,
and improved survival in patients with acute myocardial
infarction (10-13). During the early phase of acute
myocardial infarction patients will show marked
angiographic heterogeneity in collateral formation that is
independent of the status of coronary artery occlusion
(15). Collateral formation may vary from complete to
absent during the early phase of acute myocardial
infarction; however, the mechanism underlying these
large differences between individual patients in the extent
and adequacy of collateralization remains unclear.
In the present study we investigated age, gender,
plasma homocysteine concentration, lipid parameters,
hypertension, diabetes mellitus, and smoking as
determinants of early collateral development after acute
myocardial
infarction.
Plasma
homocysteine
concentration was the only independent variable that
affected the development of collaterals. There was an
inverse relation between plasma homocysteine
concentration and collateral formation. Duan et al.
reported that hyperhomocysteinemia impaired
angiogenesis in vivo in a rat model (16). Their study was
the first to provide evidence that hyperhomocysteinemia
inhibits ischemia-induced angiogenesis in vivo.
Following a search of the literature, we located only 2
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studies that investigated the association between
homocysteine concentration and collateral formation in
humans (17,18). Nagai et al. studied the effect of plasma
homocysteine concentration on collateral circulation in 49
single-vessel coronary artery disease patients (17).
Nineteen patients had single-vessel total occlusion. They
noted significantly higher plasma homocysteine
concentration in the poor collateral group. According to
their study the independent factors that affected the
development of collateral circulation in patients with
single-vessel disease were homocysteine concentration,
duration of angina pectoris, and degree of stenosis. The
other study, which included 56 cases of pure single-vessel
chronic total occlusion, reported no significant difference
in plasma homocysteine concentration between the poor
and good collateral groups (18).
Homocysteine is a risk factor for the development of
coronary artery disease (4,5). Laboratory studies suggest
that an elevated homocysteine concentration is both
atherogenic and thrombogenic (19). There may be
several
possible
mechanisms
by
which
hyperhomocysteinemia impairs angiogenesis. First,
hyperhomocysteinemia-induced endothelial dysfunction
may account for the impaired angiogenesis.
Homocysteine
reduces
endothelium-dependent
vasodilatation by elevating plasma levels of asymmetric
dimethylarginine, a potent inhibitor of nitric oxide (NO)
synthase (20). Homocysteine impairs endotheliumderived NO formation, not only in large conduit arteries,
but also in microvessels in vivo. Endothelium-derived NO
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is an important regulator of angiogenesis. For example,
endothelium-derived NO maintains endothelial cell
integrity and the expression of integrin v 3, thus
promoting endothelial podokinesis and migration
(21,22). Angiogenesis induced by vascular endothelial
growth factor was attenuated by inhibitors of NO
synthase (23).
Second, hyperhomocysteinemia-induced production of
reactive oxygen radicals may contribute to further
impairment of angiogenesis (24). Enhanced generation of
oxygen radicals in the hyperhomocysteinemia state might
further degrade NO. Third, homocysteine itself might
directly inhibit endothelial cell proliferation and/or
migration (8). Outinen et al. demonstrated that
homocysteine induced arrested growth in human
endothelial cells in vitro (25). Taken together, endothelial
dysfunction, decreased NO bioactivity, and increased
oxidative stress seem to account for impaired
angiogenesis in the hyperhomocysteinemia state in vivo.
One of the main limitations of the present study is
that the angiographically visualized collaterals were only
part of the total collateral circulation, because collateral
vessels less than 100 μm in diameter cannot be evaluated
angiographically. Another limitation is the small size of
the study population.
In conclusion, this study demonstrates for the first
time that there is an inverse relationship between the
early development of collateral circulation after acute
myocardial infarction and plasma homocysteine
concentration.
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